Stockreport

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

GeneDx Holdings Corp. - Class A  (WGS) 
PDF Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenueAccelerated exome and genome volume growth to 33% y [Read more]